

First South East Asia genomic data digitisation collaboration to improve cancer trial access

03 November 2022 | News

To accelerate the process of matching patients to the most suitable clinical trials

Oncoshot has announced one of its biggest collaborations to date with Icon Cancer Centre in Singapore, alongside Roche. Together the partners plan to facilitate more comprehensive genomic profiling data to increase access to more trial options for cancer patients.

This first-ever collaboration in South East Asia will help advance the biopharmaceutical research and development ecosystem for healthcare professionals, institutions and patients by taking a more personalised approach to care and offering people with cancer more treatment options.

Through this collaboration, Oncoshot, Icon and Roche will be able to easily identify cancer patients who are a match for existing clinical trials being run within their networks. Furthermore, real-time population matching will also enable companies and clinical research organisations (CROs) on the Oncoshot clinical trial platform to engage Icon as a preferred clinical trial centre, increasing patient access to clinical trial options for their cancer.

"With comprehensive genomic profiling (CGP) data, healthcare professionals can make more informed decisions for their patients about potential treatment options, which should include access to clinical trials of investigational new medicines," said Ying Ying Yeoh, General Manager for Roche Singapore.

As part of this collaboration, Roche will provide CGP data from tests that analyse over 300 genes known to drive cancer growth.

Image credit- From left to right: Ying Ying Yeoh, General Manager of Roche Singapore; Serena Wee, CEO of Icon ASEAN and Hong Kong; Dr Huren Sivaraj, CEO and Co-Founder of Oncoshot. (Photography by Azfian Bin Anuar; editing by Mel Marc Cornelio)